Physician profile
Samuel Solomon
NPI 1558316281
$724.28
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $666 · 2020: $58.60.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $116.95 | 2019-2020 | |
| Janssen Biotech, INC. | $105.02 | 2019 | |
| Abbvie INC. | $95.31 | 2019 | |
| Genzyme Corporation | $82.82 | 2019 | |
| Sun Pharmaceutical Industries INC. | $55.33 | 2019 | |
| Lilly USA, LLC | $51.81 | 2019 | |
| Dermira, INC. | $45.45 | 2019 | |
| Celgene Corporation | $43.08 | 2019 | |
| Galderma Laboratories, L.P. | $28.59 | 2019-2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $27.56 | 2019-2020 | |
| Ucb, INC. | $18.91 | 2019 | |
| Medimetriks Pharmaceuticals, INC. | $15.74 | 2019 | |
| Amgen INC. | $15.09 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $12.35 | 2019 | |
| Epi Health, LLC | $10.27 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Solomon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.